Medical/Pharmaceuticals
Antengene Announces Interim Financial Results for 2023 with New Clinical Data Highlighting the Growing Value of Its Pipeline
SHANGHAI and HONG KONG, Aug. 25, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), today announced its interim results for the six-months endedJune 30, 2023, and provided updates on multiple milestones achieved since the beginning of 2023. Dr. Jay Mei, Antengene's F...
Henlius 2023 H1 Results: Achieved record profits and RMB2.5 billion revenues, opening a new chapter of high-quality growth
SHANGHAI, Aug. 25, 2023 /PRNewswire/ -- Henlius (2696.HK) announced its 2023 interim results. In the first half of 2023, Henlius reported a boost in operating profits ofRMB240.0 million and revenues of RMB2.5005 billion, up by 93.9% YoY, driven by growth in core oncology products. HANQUYOU (trast...
Tigermed Reports 2023 Interim Results
HANGZHOU, China, Aug. 25, 2023 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading provider of clinical research solutions across full lifecycle of global biopharmaceutical and medical device products, announced its int...
Zhiyi Biotech Announced First Subject Dosed in the U.S. Phase 1 clinical Trial of SK10, in Development for Treatment of Chemotherapy-induced Diarrhea
GUANGZHOU, China, Aug. 25, 2023 /PRNewswire/ -- On August 23rd 2023, Zhiyi Biotech announced that the first three subjects have been dosed in the U.S. Phase 1 clinical trial of SK10, an innovative heat-killed Bacteroides fragilis product developed by Zhiyi Biotech for Chemotherapy-induced Diarrhe...
GC Biopharma to Produce Cholera Vaccines Jointly with Eubiologics
YONGIN, South Korea, Aug. 25, 2023 /PRNewswire/ -- GC Biopharma (006280.KS), a South Korean biopharmaceutical company, announced today that it has signed a MOU at its headquarters in Yongin,South Korea with Eubiologics for a co-production of Euvichol, an oral cholera vaccine. Under the MOU, bo...
AsiaMedic Sets New Standard in Healthcare with Installation of First SIGNA™ Hero 3.0T MRI Scanner in Asia-Pacific
SINGAPORE, Aug. 25, 2023 /PRNewswire/ -- AsiaMedic
3SBio announces 2023 interim results, with revenue growing over 20% year on year and pipeline value constantly enhanced
HONG KONG, Aug. 25, 2023 /PRNewswire/ -- Chinese leading biopharmaceutical company 3SBio (01530.HK) today released its 2023 interim results. Revenue in the first half of 2023 reached approximatelyRMB3,783.8 million, up 22.3% on a yearly basis. Gross profit was approximatelyRMB3,201.6 million, up ...
Everest Medicines Announces New Drug Application Acceptance by the Pharmaceutical Administration Bureau of Macao for Nefecon® for the Treatment of Primary IgA Nephropathy
SHANGHAI, Aug. 25, 2023 /PRNewswire/ -- Everest Medicines
Antheia Achieves Major Commercial Milestone
Company's first full-scale fermentation run reinforces commercial viability for a robust pipeline of Biosynthetic KSMs and APIs MENLO PARK, Calif., Aug. 25, 2023 /PRNewswire/ -- Antheia, the pharmaceutical ingredient manufacturer transforming essential medicine supply chains, today announced the...
Laekna, Inc. (2105.HK) Announces Interim Results 2023
* For the Phase II pivotal trial of Afuresertib (LAE002) + Paclitaxel for platinum-resistant recurrent ovarian cancer (PROFECTOR-II), the patients were fully enrolled and the topline data is expected in the late fourth quarter of 2023 * For the Phase Ib/III trial of Afuresertib + Fulvestrant ...
YS Biopharma Announces Purchase of Shares by Company Officers
GAITHERSBURG, Md., Aug. 25, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious disea...
Ping An Health announces 2023 interim results
Managed care business delivers robust performance Market leadership in corporate health management drives loss narrowing by 47.2% HONG KONG and SHANGHAI, Aug. 24, 2023 /PRNewswire/ -- Ping An Healthcare and Technology Company Limited ("Ping An Good Doctor" or "Ping An Health", Stock Code: 1833.H...
Akeso Announced NDA Acceptance of IL-12/lL-23 Monoclonal Antibody Ebdarokimab for Moderate-to-severe Plaque Psoriasis by China NMPA
HONG KONG, Aug. 24, 2023 /PRNewswire/ -- Akeso Inc. ("Akeso", the "Company"; 9926.HK), a commercial-stage biopharmaceutical company focused on developing and commercializing first-in-class and best-in-class innovative medicines globally, announced today that the New Drug Application (NDA) for its...
Vittra APS Unique composite by FGM is appointed as a solution to a clinical problem by the renowned agency Dental Advisor
JOINVILLE, Brazil, Aug. 24, 2023 /PRNewswire/ -- The Vittra APS Unique composite, by FGM Dental Group, was recognized for its chameleon effect in the publication Clinical Problem Solvers of the renowned American agency Dental Advisor - a global reference in the field of dentistry. In the publicat...
111, Inc. Announces Second Quarter 2023 Unaudited Financial Results
SHANGHAI, Aug. 24, 2023 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced its unaudited financial results for the second quar...
MRI Software's first 'Voice of the Strata Manager' report reveals unseen pressures of high-demand real estate industry job
Despite dealing with difficult behaviour from owners and 50+ hour work weeks, strata managers are optimistic about the future of their jobs and industry SYDNEY, Aug. 24, 2023 /PRNewswire/ -- A new national 'Voice of the Strata Manager' report reveals an alarming number of Australian strata manage...
PeptiGrowth Inc. and Orizuru Therapeutics, Inc. Enter into Joint Development of Novel Synthetic Peptide Based Growth Factor
TOKYO, Aug. 23, 2023 /PRNewswire/ -- PeptiGrowth Inc (PeptiGrowth), a Japanese biotechnology company focusing on the development of synthetic peptide based growth factors and Orizuru Therapeutics, Inc(OZTx), a Japanese biopharmaceutical company focusing on the research and development of iPSC-de...
Everest Medicines Announces Interim Results for First Half of 2023
SHANGHAI, Aug. 24, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, today announced its interim results for the first half of 2023, ...
Samsung Biologics appoints new leadership to oversee quality and regulatory affairs
- Distinguished industry leaders with extensive track records in quality assurance and regulatory affairs join Samsung Biologics to support the company's quality-driven business operation. INCHEON, South Korea, Aug. 23, 2023 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract d...
Salvia BioElectronics: First-Ever Patient Treated with Breakthrough Neuromodulation Solution for Severe Migraine and Cluster Headache in Australia
NAMBOUR, Australia, Aug. 24, 2023 /PRNewswire/ -- In a remarkable medical milestone, an Australian patient at Nambour Selangor Private Hospital became the first-ever patient to receive Salvia BioElectronics' paper-thin neuromodulation solution for severe migraine and cluster headache. This groun...
Week's Top Stories
Most Reposted
LINKDOOD Breaks Language Barriers, Ushering a New Era for Cross-Border Romance
[Picked up by 326 media titles]
2024-04-29 06:00Multiple achievements made in China-Hungary BRI conference
[Picked up by 314 media titles]
2024-05-03 06:59Dow showcases circular and innovative materials science solutions and industry collaborations at Chinaplas 2024
[Picked up by 295 media titles]
2024-04-30 10:11Xinhua president, Hungarian economy minister vow to bolster media cooperation
[Picked up by 284 media titles]
2024-05-03 06:25TAILG Makes Grand Appearance at 2024 Asiabike Jakarta, Aiming to Set the Benchmark in Indonesia
[Picked up by 259 media titles]
2024-05-02 01:21